Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: CTSU E3805 Principal Investigator: Picus, Joel
Title: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer.
Phase: III Disease Site: Prostate
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to determine whether giving docetaxel chemotherapy, at the time you are starting hormonal therapy and when the hormonal therapy is no longer working, is more effective than giving it only at the time the hormonal therapy is no longer working. Hormonal therapy refers to drugs or surgical procedures such as an orchiectomy (removal of one or both testicles) used to lower your testosterone. This puts prostate cancer into remission in most patients as the testosterone is like a fuel for the cancer. It is the standard to give this as the only treatment for your cancer. Normally chemotherapy is reserved for when a patient’s cancer starts to grow again despite having a low testosterone level. In this study you will either get docetaxel when you start your hormonal therapy or when/if your cancer grows with a low testosterone level. If you have chemotherapy when you start hormones for the first time, you may get chemotherapy when/if your cancer grows back with a low testosterone level.

About 568 people will take part in this study with approximately 15 being from Washington University.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)